Based on technology from Rockefeller University, Virdante is focused on the development of novel therapeutics for autoimmune and inflammatory disorders. Using a proprietary “sialic switch” technology, the company aims to improve the anti-inflammatory properties of intravenous immunoglobulin (IVIG) antibodies. Virdante was acquired by Momenta Pharmaceuticals in 2011.